Exos Asset Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Exos Asset Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,933	Closed	-$22K	–	744
2021 Q2	$22K	Hold	21,933	–	–	0.01%	684
2021 Q1	$13K	Buy	+21,933	New	+$21.2K	0.01%	356

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Exos Asset Management's EFTRW Position: Q3 2021 in Review

Exos Asset Management sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 21,933 shares — an estimated $22K sold.

Exos Asset Management first reported a position in EFTRW in Q1 2021 and held it in 2 quarters. The position peaked at $22K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

Exos Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Exos Asset Management sold 21,933 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $22K.
Exos Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 2 quarters.
Exos Asset Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $22K in Q2 2021.
21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.